Infectious complications after transrectal ultrasound–guided prostate biopsy (TRUSPB) have increased in recent years.

The Problem:

Fecal carriage of fluoroquinolone-resistant E. coli strains is an important risk factor for infectious complications after TRUSPB.  In addition, the incidence of ESBL-producing bacteria has increased in many countries.  Many ESBL-producing bacteria are resistant not only to penicillins and cephalosporins, but also to fluoroquinolones and aminoglycosides.  This underscores the need to find new strategies to fight this problem.

A New Tool in the Fight Against Post-TRUSPB Complications:

MicroPathID – Pre-Prostate Biopsy Panel (PBx)Provides rapid molecular identification of 17 pathogenic bacteria and fungal species associated with potential infectious complications following TRUSPB and detection of up to 36 genes that confer antibiotic resistance across 10 drug classes.  Confirmatory culture and susceptibility results are provided to help guide antibiotic selection and assist with antimicrobial stewardship.

Rapid PCR Detection
17 Pathogenic Bacteria
and Fungal Species

Acinetobacter baumannii
Citrobacter freundii
Enterobacter aerogenes
Enterobacter cloacae
Enterococcus faecalis
Enterococcus faecium
Escherichia coli
Klebsiella oxytoca
Klebsiella pneumoniae
Morganella morganii
Proteus mirabilis
Proteus vulgaris
Staphylococcus aureus
Pseudomonas aeruginosa
Staphylococcus saprophyticus
Streptococcus agalactiae
Candida albicans

Rapid PCR Detection
 36 Gene Antibiotic
Resistance Panel
~10 Drug Classes

AmpC beta lactamase
Extended Spectrum Betalactamase
Macrolides, lincosamides, streptogramins

Confirmatory Culture
and Susceptibility

Antibiotic Susceptibility

Conventional Cultures:

  • Are unable to produce growth in certain pathogens
  • Require 48-72 hours for results

Clinical Advantages:  MicroPathID – PBx Panel

  • Rapid PCR results on pathogen identification and antibiotic resistance
    • 12 – 24 hours from specimen receipt
  • Improved Sensitivity
    • 3-5X more sensitive than conventional culture
  • Can detect polymicrobial infections
  • Unaffected by concurrent antibiotic use
  • Culture confirmation and susceptibility
    • Phenotypic characterization combined with genotypic information for improved outcomes

The Process

The PBx Panel is performed by Bostwick Laboratories from a rectal swab specimen collected prior to administration of prophylactic antibiotics.

Day 1
Collect rectal swab specimen

Day 2
Specimen arrives at Bostwick Laboratories – PCR testing and cultures begin

Day 2-3
Receive PCR results of 17 pathogens and Antibiotic Resistance Genes

Day 4
Receive confirmatory culture and susceptibility results

Day 4
Informed prophylaxis antibiotic selection

For more information about Bostwick Laboratories click the logo below to visit their full site.